From a media Webinar: The Science Behind Botox: A 20-Year Perspective:
The good people who bring you The Real Housewives of NYC have a message for you, and no, I’m not talking about the Bravo network. (Although I have a message for them: KEEP IT COMING!)
I’m talking about the makers of Botox, of course, and the message they tried to convey in an hour-long media Webinar today was that Reloxin is coming, but we ain’t scared. (Or, scuuurrrred, for the young’uns out there.)
“We have a world share of around 83%” of the botulinum toxin market, said David Pyott, CEO of Allergan, the maker of Botox. “We’re outselling the competitors by about seven times. And in the hands of thousands of physicians across many countries around the world, faced with the data…physicians have made their choice. And that’s a very important fact for people to consider.”
Reloxin isn’t even approved in the U.S. yet, though it is expected soon. Makes you wonder, though: If the facts speak for themselves, why call this conference? Worried about losing some of that market share?
—Denise Napoli @Denisenapoli